DeepValue | The New Way Investors Work

AeroVironment has quickly become one of the market’s favorite ways to play the “modern warfare” theme: drones, loitering munitions, and counter‑UAS systems tied to elevated U.S. and allied defense spending. The October 2025 Freedom Eagle (FE‑1) missile win and a massive $874 million foreign military sales IDIQ added more jet fuel to that narrative, and the May 2025 BlueHalo acquisition pushed the story into space, cyber, and directed energy as well.

But when we step away from the contract headlines and look through the SEC filings and management’s own guidance, a more nuanced picture emerges. At roughly $257 per share, our team believes AeroVironment (NASDAQ: AVAV) has become a high‑expectations execution story, not a classic value setup with a margin of safety baked in.

Record bookings and book‑to‑bill of 2.9 in FY2026 Q2 are real positives. Yet gross margin has reset to the low‑20% range, free cash flow is negative, and GAAP earnings are being crushed by BlueHalo‑related amortization and working‑capital build. According to the 10‑Q (2025), filed Dec 10 2025, the company posted $(168.8) million of operating cash outflow over just six months.

Our bottom line: we rate AVAV a WAIT at current levels. The stock can work, but only if the next 6–9 months prove that demand converts into margin and cash, not just revenue and press releases.

If you’re tracking defense tech names like AVAV, you can use our deep research engine to turn hours of 10‑K/10‑Q reading into minutes and compare multiple stocks side‑by‑side with standardized reports.

Run Deep Research on AVAV →

Investment snapshot: A high‑expectations “modern warfare” winner

AeroVironment is a Delaware corporation headquartered in Arlington, VA, best known for its uncrewed aircraft systems, loitering munitions (like Switchblade), and counter‑UAS solutions. After closing the BlueHalo acquisition on May 1, 2025, it repositioned itself as a “next‑gen defense tech prime” spanning air, land, sea, space, and cyber, with two reportable segments:

Autonomous Systems (AxS)
Space, Cyber and Directed Energy (SCDE)

According to the 10‑K (2025), filed Jun 25 2025, fiscal 2025 (pre‑BlueHalo close) delivered record revenue of $820.6 million and bookings of $1.2 billion, with a 12% gross margin improvement year over year. Post‑acquisition, FY2026 Q2 results show how dramatically the scale has changed:

FY2026 Q2 revenue: $472.5 million
FY2026 first‑half segment adjusted EBITDA: $101.5 million
But loss before income taxes for the first half: $(104.9) million, weighed down by $148.3 million of depreciation and amortization, $32.0 million of acquisition‑related expenses, and nearly $20.0 million of stock‑based compensation, per the 10‑Q (2025), filed Dec 10 2025.

On the surface, the top line looks fantastic. Underneath, earnings quality and cash generation are the real battleground.

Our rating framework: Why we’re at “WAIT”

Rating: WAIT
Conviction: 4.0 (on our scale, that’s a reasonably strong but not maximal view)
Attractive entry: ~$220
Trim above: ~$310
Re‑assessment window: 3–6 months

We see AVAV as fairly valued to slightly rich relative to the current fundamentals. The market is already paying up for:

Fast conversion of record bookings into cash earnings
A quick fade of BlueHalo integration drag
A rebound in gross margin and non‑GAAP EPS

At ~$257, our base‑case intrinsic value estimate sits around $270, with a 50% probability weight. That leaves limited upside unless the company executes toward our bull case more quickly than expected.

What is the core AVAV investment thesis today?

Our thesis is straightforward:

AVAV is strategically well positioned in high‑growth defense niches (UAS, loitering munitions, counter‑UAS, and now missile‑adjacent via FE‑1).
Demand signals are strong: record bookings, a very high book‑to‑bill ratio, and a big pipeline of IDIQ ceilings and initial program wins.
But the stock already assumes that this demand will quickly translate into:
Gross margin in the mid‑20s or better
Rising non‑GAAP EPS (after a recent guidance cut)
Stronger operating and free cash flow

The company’s own guidance captures the tension. For FY2026, management is calling for:

Revenue: $1.95–2.0 billion
Adjusted EBITDA: $300–320 million
Gross margin: stuck in the 21–22% range
Non‑GAAP EPS: cut to $3.40–3.55 from $3.60–3.70, as disclosed in the Dec 9 2025 Q2 results press release.

At current prices, buying AVAV really pays off only if:

1. Gross margin moves above 25% within the next two quarters, and

2. Cash conversion inflects, closing the gap between adjusted EBITDA and operating cash flow.

Until we see those two things, we treat the stock as a crowded, high‑bar execution story, not a bargain.

Is AVAV stock a buy in 2026?

For a long‑term investor asking “Is AVAV stock a buy in 2026?”, we would frame it this way:

If you already own it: We would lean toward holding a right‑sized position while watching margins and cash carefully.
If you’re on the sidelines: We’d wait for either a better price (closer to our ~$220 “attractive entry” zone) or clear evidence that the execution thesis is playing out.

There are three scenario paths we model:

Base case (50% probability, implied value ~$270)

ERP stabilization and process clean‑up slow the working‑capital build.
Cash conversion improves without a dramatic change in business mix.
FY2026 gross margin rises to the 24–26% range.
FY2026 non‑GAAP EPS holds at $3.40–3.55.

In this world, the stock is roughly fairly priced today, and your returns depend mainly on how the market values defense growth names 12–24 months from now.

Bear case (30% probability, implied value ~$210)

BlueHalo services remain a large share of the mix, pressuring product margins.
SCDE does not meaningfully improve on a segment adjusted EBITDA basis.
FY2026 gross margin stays stuck at 21–23%.
Operating cash flow remains negative into FY2027.

In this outcome, the market re‑rates AVAV to a structurally lower‑margin profile, and today’s price would likely imply permanent capital impairment.

Bull case (20% probability, implied value ~$320)

Follow‑on funded task orders convert big IDIQ ceilings (like the $874 million FMS contract) into high‑margin production volume.
SCDE turns sustainably positive on adjusted EBITDA.
Consolidated gross margin pushes into the 27–29% range.

Here, the narrative and earnings power line up, and AVAV could grow into a premium multiple. But a lot has to go right quickly, particularly around BlueHalo integration and working‑capital discipline.

Will AeroVironment deliver long‑term growth?

On the demand side, we think the answer is yes: AeroVironment has strong long‑term growth potential. The question is how much of that growth you, as a shareholder, actually keep in the form of free cash flow and per‑share earnings.

Key growth drivers include:

Elevated U.S. and allied appetite for UAS, loitering munitions, and counter‑UAS, as evidenced by FY2026 Q2 bookings of $1.4 billion and a book‑to‑bill ratio of 2.9 according to the Dec 9 2025 Q2 press release.
The $874.26 million five‑year FMS IDIQ that broadens the pipeline of foreign military orders across multiple platforms, per the Dec 8 2025 IDIQ announcement.
FE‑1 / Freedom Eagle, which moves AVAV into the missile lane long dominated by large primes, as detailed in the Oct 22 2025 FE‑1 award release.

But long‑term value creation will depend on three financially grounded milestones:

1. Absorbing $708.9 million of acquired intangible amortization over five years without starving R&D or capacity investment, as disclosed in the 10‑K (2025), filed Jun 25 2025.

2. Avoiding more goodwill/intangible impairments, after prior charges of $18.4 million in 2025 and $156.0 million in 2023.

3. Stabilizing working capital and generating predictable free cash flow, so bookings and adjusted EBITDA translate into cash, not just accounting earnings.

In other words, top‑line growth looks very likely. The battle is over margin structure and cash conversion.

Margin of safety: Why we don’t see one today

From a classic value‑investing lens, AVAV currently offers no real margin of safety.

Based on our report:

Valuation multiples are elevated:
P/E: roughly ‑103x (GAAP negative earnings)
EV/EBITDA: about 127.5x
Free cash flow is negative, with recent quarterly FCF of about $(67.8) million and operating cash outflow of $(168.8) million over six months, per the 10‑Q (2025), filed Dec 10 2025.
Interest coverage is negative (‑4.31), reflecting the heavy non‑cash amortization drag and new debt burden post‑BlueHalo.
The balance sheet is loaded with goodwill and intangibles (goodwill stood at $2.62 billion as of Nov 1 2025), rather than hard assets that would support downside in a stress scenario, as laid out in the 10‑K (2025), filed Jun 25 2025.

Yes, liquidity is decent, with $359.4 million of cash on hand at the end of the FY2026 Q2 period, per the 10‑Q (2025). But your downside protection does not come from:

Stable free cash flow
Asset backing
Contractually locked‑in revenue

Instead, you are paying for execution: the ability to restore margins, convert backlog to cash, and make SCDE economically productive.

For us, that pushes AVAV firmly into “position‑sizing discipline” territory. It is not a stock we would hide in and forget about; it’s one we would monitor closely with tight thesis checkpoints.

For names like AVAV where the thesis hinges on execution, our platform gives you citation‑backed reports and direct links into every 10‑K, 10‑Q, and 8‑K we reference so you can trust‑but‑verify the story.

See the Full Analysis →

Revenue mechanics and why backlog isn’t “locked in”

One of the most common mistakes we see in market coverage is treating AVAV’s backlog like guaranteed future revenue. The filings are explicit that this is not the case.

How AVAV makes money

The business is a mix of:

Product sales: uncrewed aircraft systems, loitering munitions, counter‑UAS hardware, and now missile‑type products like FE‑1.
Services: training, logistics, engineering, customer‑funded R&D, and other support.

Pre‑BlueHalo, the mix skewed more toward product‑rich segments like UxS and LMS. Post‑BlueHalo, management expects a higher proportion of services, which typically carry:

Lower gross margins
Different working‑capital dynamics (more unbilled receivables, longer cycles)

Cost of sales scales with volume and mix (for example, Switchblade production shifts can dilute margins), while SG&A and R&D include a heavy fixed component, now loaded with BlueHalo‑related amortization, integration costs, and additional headcount.

Backlog: Funded vs unfunded

As of Nov 1 2025, per the 10‑Q (2025), filed Dec 10 2025:

Funded backlog: ~$1.09 billion
Unfunded backlog: ~$2.79 billion

Management explicitly states that:

Unfunded backlog does not meet the definition of a performance obligation.
Many U.S. government contracts can be terminated for convenience.
Backlog can swing significantly quarter to quarter.

So the eye‑popping $3.9+ billion combined backlog is not a cash flow annuity. It’s a pipeline of potential work with meaningful timing and execution risk.

Working capital and cash conversion

The 10‑Q makes the problem plain: operating cash flow used $(168.8) million in the six months ended Nov 1 2025, even as segment adjusted EBITDA looked healthy. The main culprits were:

Rising unbilled receivables
Higher accounts receivable
Larger inventories

This tells us that:

The company is working hard to stand up and execute on a lot of new orders.
But cash collection lags the accounting recognition of revenue and EBITDA.

For the thesis to work, this gap must narrow over the next few quarters.

BlueHalo and SCDE: Growth engine or structural drag?

BlueHalo is the pivot point in the AVAV story. It expanded the company’s footprint across space, cyber, and directed energy and enabled wins like FE‑1 and the large FMS IDIQ. But financially, it’s been a double‑edged sword so far.

According to the 10‑Q (2025), filed Dec 10 2025:

In the six months post‑close, BlueHalo contributed:
$480.3 million of revenue
$(129.4) million of operating loss
Including $120.4 million of intangible amortization

SCDE, the segment that now houses most BlueHalo activity, posted:

Revenue of $340.3 million over six months
Segment adjusted EBITDA of $(2.3) million

So:

On an adjusted basis: SCDE is roughly breakeven.
On a GAAP basis: it’s a sizable drag due to amortization and integration costs.

Management projects $708.9 million of acquired‑intangible amortization over the next five years, per the 10‑K (2025). That’s a structural headwind you can’t simply ignore.

For BlueHalo to justify its price tag and debt load, we need to see:

Sustained positive segment adjusted EBITDA in SCDE
Rising margins as integration synergies and cross‑selling kick in
No repeat of the sizeable goodwill/intangible impairments seen in FY2023 and FY2025

If SCDE simply becomes a revenue engine with near‑zero economics, the market will ultimately compress AVAV’s multiple, no matter how good the top‑line growth looks.

Market sentiment: Crowded “defense drone” narrative with hidden fragility

The mainstream narrative around AVAV is extremely bullish on demand but increasingly cautious on profitability.

Recent coverage, including Trefis, Jan 2026, Barron’s, Dec 2025, and The Motley Fool, Jan 2026, tends to highlight:

Big contract wins and surging bookings
The stock’s sharp rallies on award announcements
But also sharp drawdowns when EPS misses expectations or guidance is cut

We see several important takeaway points for investors:

1. The narrative is crowded. Many outlets repeat the same “defense drones + big Army contracts” framing, making it harder to gain edge just by reading headlines.

2. Price action is event‑driven. Multi‑day 30–50% rallies and subsequent corrections around contracts and earnings point to fragile positioning.

3. Profitability is under real scrutiny. As Barron’s and others have noted, “record sales” have not prevented steep sell‑offs when margins or EPS disappoint.

That combination reinforces why we’re demanding tangible improvement in gross margin and cash flow before upgrading AVAV to a buy.

If you want to systematically separate signal from noise across multiple names in this space, Read our AI-powered value investing guide to see how tools like DeepValue can automate the deep research behind these narratives.

Key risks and monitoring checklist for AVAV investors

For a stock like AVAV, we think investors should pre‑define clear “breakpoints” where the thesis is either validated or needs to be cut back. Our checklist looks like this.

90‑day checkpoints (through roughly May 2026)

From the Dec 9 2025 Q2 press release and Sep 9 2025 Q1 release:

If FY2026 Q3 gross margin does not improve from the ~21–22% range and management cuts FY2026 non‑GAAP EPS guidance again

Thesis weakens; we would reduce exposure.

If funded backlog holds at or above ~$1.1 billion and book‑to‑bill stays >1

Demand side looks intact; the focus remains execution and cash.

If SCDE segment adjusted EBITDA turns positive and improves sequentially, and operating cash flow improves

That would be an early sign that BlueHalo is moving from drag to contributor; we’d consider adding on weakness.

6–18 month milestones

FMS IDIQ conversion: By mid‑FY2027 planning cycles, we want to see the $874.26 million FMS IDIQ generating disclosed funded delivery orders or task orders, per the Dec 8 2025 IDIQ release. If not, we’d treat it as a “ceiling story” with limited earnings power.
FE‑1 follow‑on: For FE‑1, we’ll be watching for follow‑on lots, options, or exercises beyond the initial $95.9 million, as described in the Oct 22 2025 FE‑1 announcement. Without that, the “missile adjacency” thesis loses steam.
Cash conversion: Operating cash flow needs to swing positive and stay there, with working capital growing more slowly than revenue.

Early warning indicators

We would treat the following as red flags:

Book‑to‑bill dropping below 1 while funded backlog rolls over, despite more IDIQ announcements.
Gross margin stuck near 21–22% for multiple quarters post‑BlueHalo.
SCDE repeatedly posting negative segment adjusted EBITDA, indicating that integration and cross‑selling are not driving profitability.

In any of those scenarios, we’d question whether the current valuation can hold.

Management quality, governance, and incentives

Management’s track record is mixed:

On the plus side, they scaled the legacy business into record revenue and profitability through FY2025.
On the minus side, the BlueHalo step‑change has so far brought:
Sustained margin compression
Heavier amortization and integration noise
A cut to FY2026 non‑GAAP EPS guidance despite strong bookings

The company’s adoption of Oracle Fusion ERP is a necessary upgrade for scale, but it also introduces internal control and process risk in the near term, as highlighted in the 10‑K (2025), filed Jun 25 2025.

From a governance and incentive perspective, the DEF 14A (2025), filed Aug 13 2025 shows that:

Annual bonuses emphasize consolidated revenue, bookings, and adjusted EBITDA.
Adjusted EBITDA explicitly excludes acquisition‑related costs and stock‑based compensation.

That structure creates a risk that management optimizes for adjusted metrics while GAAP EPS and free cash flow lag. As shareholders, we care about cash and per‑share economics, not just adjusted EBITDA.

On capital allocation, the BlueHalo deal fundamentally changed the balance sheet:

New $700 million term loan and $350 million revolver
Equity and convertible debt issuance
A large amortization burden locked in for years

The success of that decision hinges on turning SCDE into a profitable, cash‑generating segment. If that does not happen, the acquisition will look expensive in hindsight.

How we’d approach AVAV as investors

Pulling everything together, here’s how we, as the DeepValue team, would think about AVAV in a portfolio:

Role: High‑beta defense growth name with heavy execution risk, not a core, sleep‑easy holding.
Sizing: Modest position size, with willingness to add on evidence of margin and cash inflection or cut on renewed guidance cuts.
Time horizon: 12–24 months to see whether BlueHalo and FE‑1 transition from narrative to durable earnings.

Key thresholds we’d want to see before moving from “WAIT” to “BUY”:

1. Gross margin trending toward 24–26% and away from the current 21–22% post‑BlueHalo levels disclosed in the FY2026 Q1 and Q2 releases and Dec 9 2025 Q2 results.

2. Non‑GAAP EPS guidance at least holding or being revised upward, with no additional cuts into FY2026 year‑end.

3. Operating cash flow turning positive and staying there, demonstrating that working capital is stabilizing and EBITDA is becoming real cash.

4. SCDE delivering sustained positive segment adjusted EBITDA.

If those pieces fall into place, AVAV could justify a premium multiple and reward patient investors. If they don’t, the downside scenario of multiple compression and capital impairment becomes much more likely.

Instead of hand‑reading every 10‑K, 10‑Q, and press release yourself, you can use our deep research agent to generate a full, cited AVAV report in about five minutes and benchmark it against other defense tech names.

Research AVAV in Minutes →

AeroVironment (AVAV) Deep Research Report: High-Expectation Defense Play or Premature Entry?